Understanding the relationship between GSK-3 and Alzheimer’s disease: a focus on how GSK-3 can modulate synaptic plasticity processes

References

• Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug discovery and Development. Martínez A, Castro A, Medina M. (Eds). Wiley Series in Drug Discovery and Development. Wiley-Interscience. John Wiley and Sons, NJ, USA (2006).
   Google Scholar
• Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer’s disease. Curr. Pharm. Des. 16(25), 2790–2798 (2010).
   PubMedGoogle Scholar
• Medina M, Garrido JJ, Wandosell FG. Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front. Mol. Neurosci. 4, 24 (2011).
   PubMed Web of Science ®Google Scholar
• Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3 – an overview of an over-achieving protein kinase. Curr. Drug Targets 7(11), 1377–1388 (2006).
   PubMed Web of Science ®Google Scholar
• Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J. Neurochem. 81(5), 1073–1083 (2002).
   PubMed Web of Science ®Google Scholar
• Schaffer B, Wiedau-Pazos M, Geschwind DH. Gene structure and alternative splicing of glycogen synthase kinase 3β (GSK-3β) in neural and non-neural tissues. Gene 302(1–2), 73–81 (2003).
   PubMedGoogle Scholar
• Medina M, Wandosell F. Deconstructing GSK-3: the fine regulation of its activity. Int. J. Alz. Dis. 2011, 479249 (2011).
   Google Scholar
• Caricasole A, Copani A, Caraci F et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer’s brain. J. Neurosci. 24(26), 6021–6027 (2004).
   PubMed Web of Science ®Google Scholar
• Kaidanovich-Beilin O, Beaulieu JM, Jope RS, Woodgett JR. Neurological functions of the masterswitch protein kinase – GSK-3. Front. Mol. Neurosci. 5, 48 (2012).
   PubMedGoogle Scholar
• Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates – Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20(3), 127–150 (2012).
   PubMedGoogle Scholar
• Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J. Psychiatry Neurosci. 37(1), 7–16 (2012).
   PubMed Web of Science ®Google Scholar
• Liu KJ, Arron JR, Stankunas K, Crabtree GR, Longaker MT. Chemical rescue of cleft palate and midline defects in conditional GSK-3β mice. Nature 446(7131), 79–82 (2007).
   PubMedGoogle Scholar
• O’Brien WT, Harper AD, Jové F et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24(30), 6791–6798 (2004).
   PubMed Web of Science ®Google Scholar
• Kimura T, Yamashita S, Nakao S et al. GSK-3β is required for memory reconsolidation in adult brain. PLoS ONE 3(10), e3540 (2008).
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Zhang X, Rodriguiz RM et al. Role of GSK3 β in behavioral abnormalities induced by serotonin deficiency. Proc. Natl Acad. Sci. USA 105(4), 1333–1338 (2008).
   PubMed Web of Science ®Google Scholar
• Prickaerts J, Moechars D, Cryns K et al. Transgenic mice overexpressing glycogen synthase kinase 3β: a putative model of hyperactivity and mania. J. Neurosci. 26(35), 9022–9029 (2006).
   PubMed Web of Science ®Google Scholar
• Latapy C, Rioux V, Guitton MJ, Beaulieu JM. Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367(1601), 2460–2474 (2012).
   PubMed Web of Science ®Google Scholar
• MacAulay K, Doble BW, Patel S et al. Glycogen synthase kinase 3α-specific regulation of murine hepatic glycogen metabolism. Cell Metab. 6(4), 329–337 (2007).
   PubMed Web of Science ®Google Scholar
• Kaidanovich-Beilin O, Lipina TV, Takao K et al. Abnormalities in brain structure and behavior in GSK-3α mutant mice. Mol. Brain 2, 35 (2009).
   PubMed Web of Science ®Google Scholar
• Hurtado DE, Molina-Porcel L, Carroll JC et al. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer’s disease. J. Neurosci. 32(21), 7392–7402 (2012).
   PubMed Web of Science ®Google Scholar
• Patel SJ, Jindal R, King KR, Tilles AW, Yarmush ML. The inflammatory response to double stranded DNA in endothelial cells is mediated by NF-κB and TNFa. PLoS ONE 6(5), e19910 (2011).
   Google Scholar
• Kim WY, Wang X, Wu Y et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat. Neurosci. 12(11), 1390–1397 (2009).
   PubMed Web of Science ®Google Scholar
• Eom TY, Jope RS. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3α/β impairs in vivo neural precursor cell proliferation. Biol. Psychiatry 66(5), 494–502 (2009).
   PubMed Web of Science ®Google Scholar
• Polter AM, Yang S, Jope RS, Li X. Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell. Signal. 24(1), 265–271 (2012).
   PubMed Web of Science ®Google Scholar
• Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP. The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer’s disease. Acta Neuropathol. 103(2), 91–99 (2002).
   PubMed Web of Science ®Google Scholar
• Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between β amyloid peptide and tau protein. Exp. Neurol. 223(2), 322–325 (2010).
   PubMed Web of Science ®Google Scholar
• Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J. Neurochem. 104(6), 1433–1439 (2008).
   PubMed Web of Science ®Google Scholar
• Ittner LM, Götz J. Amyloid-β and tau – a toxic pas de deux in Alzheimer’s disease. Nat. Rev. Neurosci. 12(2), 65–72 (2011).
   PubMed Web of Science ®Google Scholar
• Muyllaert D, Kremer A, Jaworski T et al. Glycogen synthase kinase-3β, or a link between amyloid and tau pathology? Genes Brain Behav. 7(Suppl. 1), 57–66 (2008).
   PubMed Web of Science ®Google Scholar
• Hoshi M, Sato M, Matsumoto S et al. Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl Acad. Sci. USA 100(11), 6370–6375 (2003).
   PubMed Web of Science ®Google Scholar
• Mateo I, Infante J, Llorca J, Rodríguez E, Berciano J, Combarros O. Association between glycogen synthase kinase-3β genetic polymorphism and late-onset alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 21(4), 228–232 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang N, Yu JT, Yang Y, Yang J, Zhang W, Tan L. Association analysis of GSK3B and MAPT polymorphisms with Alzheimer’s disease in Han Chinese. Brain Res. 1391, 147–153 (2011).
   PubMedGoogle Scholar
• Schaffer BA, Bertram L, Miller BL et al. Association of GSK3B with Alzheimer’s disease and frontotemporal dementia. Arch. Neurol. 65(10), 1368–1374 (2008).
   PubMedGoogle Scholar
• Kwok JB, Loy CT, Hamilton G et al. Glycogen synthase kinase-3β and tau genes interact in Alzheimer’s disease. Ann. Neurol. 64(4), 446–454 (2008).
   PubMed Web of Science ®Google Scholar
• Mateo I, Vázquez-Higuera JL, Sánchez-Juan P et al. Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3β) and Alzheimer’s disease risk. Acta Neurol. Scand. 120(2), 130–133 (2009).
   PubMedGoogle Scholar
• Kwok JB, Hallupp M, Loy CT et al. GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease. Ann. Neurol. 58(6), 829–839 (2005).
   PubMed Web of Science ®Google Scholar
• Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84(2), 361–384 (2004).
   PubMed Web of Science ®Google Scholar
• Jaworski T, Kügler S, Van Leuven F. Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer’s disease. Int. J. Alzheimers. Dis. 2010, pii: 573138 (2010).
   PubMedGoogle Scholar
• Pérez M, Hernández F, Lim F, Díaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5(4), 301–308 (2003).
   PubMed Web of Science ®Google Scholar
• Noble W, Planel E, Zehr C et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102(19), 6990–6995 (2005).
   PubMed Web of Science ®Google Scholar
• Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 103(23), 8864–8869 (2006).
   PubMed Web of Science ®Google Scholar
• Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat. Rev. Drug Discov. 8(10), 783–793 (2009).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118(1), 53–69 (2009).
   PubMed Web of Science ®Google Scholar
• Bretteville A, Planel E. Tau aggregates: toxic, inert, or protective species? J. Alzheimers Dis. 14(4), 431–436 (2008).
   PubMed Web of Science ®Google Scholar
• Congdon EE, Duff KE. Is tau aggregation toxic or protective? J. Alzheimers Dis. 14(4), 453–457 (2008).
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8(2), 101–112 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. A beta-oligomers – a decade of discovery. J. Neurochem. 101(5), 1172–1184 (2007).
   PubMed Web of Science ®Google Scholar
• Gómez-Ramos A, Díaz-Hernández M, Cuadros R, Hernández F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 580(20), 4842–4850 (2006).
   PubMed Web of Science ®Google Scholar
• Gómez-Ramos A, Díaz-Hernández M, Rubio A, Miras-Portugal MT, Avila J. Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol. Cell. Neurosci. 37(4), 673–681 (2008).
   PubMed Web of Science ®Google Scholar
• Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284(19), 12845–12852 (2009).
   PubMed Web of Science ®Google Scholar
• Clavaguera F, Bolmont T, Crowther RA et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11(7), 909–913 (2009).
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30(49), 16559–16566 (2010).
   PubMed Web of Science ®Google Scholar
• Chai X, Wu S, Murray TK et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J. Biol. Chem. 286(39), 34457–34467 (2011).
   PubMed Web of Science ®Google Scholar
• Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr. Opin. Immunol. 21(3), 359–363 (2009).
   PubMed Web of Science ®Google Scholar
• Medina M. Recent developments in tau-based therapeutics for neurodegenerative diseases. Recent Pat. CNS Drug Discov. 6(1), 20–30 (2011).
   PubMedGoogle Scholar
• Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J. Alzheimers Dis. 15(2), 157–168 (2008).
   PubMed Web of Science ®Google Scholar
• De Ferrari GV, Papassotiropoulos A, Biechele T et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset alzheimer’s disease. Proc. Natl Acad. Sci. USA 104(22), 9434–9439 (2007).
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. 33(Pt 5), 1041–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton G, Proitsi P, Jehu L et al. Candidate gene association study of insulin signaling genes and Alzheimer’s disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(4), 508–516 (2007).
   PubMedGoogle Scholar
• Reiman EM, Webster JA, Myers AJ et al. GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers. Neuron 54(5), 713–720 (2007).
   PubMed Web of Science ®Google Scholar
• Sayas CL, Avila J, Wandosell F. Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3. Biochim. Biophys. Acta 1582(1–3), 144–153 (2002).
   PubMedGoogle Scholar
• Jackson GR, Wiedau-Pazos M, Sang TK et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34(4), 509–519 (2002).
   PubMed Web of Science ®Google Scholar
• Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J. 377(Pt 1), 249–255 (2004).
   PubMedGoogle Scholar
• Cole AR, Causeret F, Yadirgi G et al. Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J. Biol. Chem. 281(24), 16591–16598 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120(1), 137–149 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang H, Guo W, Liang X, Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell 120(1), 123–135 (2005).
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 298(5594), 789–791 (2002).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192(1), 106–113 (2008).
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature 423(6938), 435–439 (2003).
   PubMed Web of Science ®Google Scholar
• Su Y, Ryder J, Li B et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing. Biochemistry 43(22), 6899–6908 (2004).
   PubMed Web of Science ®Google Scholar
• Sun X, Sato S, Murayama O et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321(1–2), 61–64 (2002).
   PubMed Web of Science ®Google Scholar
• Jaworski T, Dewachter I, Lechat B et al. GSK-3a/β kinases and amyloid production in vivo. Nature 480(7376), E4–E5; discussion E6 (2011).
   PubMedGoogle Scholar
• Palacino JJ, Murphy MP, Murayama O et al. Presenilin 1 regulates β-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J. Biol. Chem. 276(42), 38563–38569 (2001).
   PubMed Web of Science ®Google Scholar
• Tesco G, Tanzi RE. GSK3β forms a tetrameric complex with endogenous PS1-CTF/NTF and β-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann. NY Acad. Sci. 920, 227–232 (2000).
   PubMedGoogle Scholar
• Twomey C, McCarthy JV. Presenilin-1 is an unprimed glycogen synthase kinase-3β substrate. FEBS Lett. 580(17), 4015–4020 (2006).
   PubMedGoogle Scholar
• Baki L, Shioi J, Wen P et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23(13), 2586–2596 (2004).
   PubMed Web of Science ®Google Scholar
• Rockenstein E, Torrance M, Adame A et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27(8), 1981–1991 (2007).
   PubMed Web of Science ®Google Scholar
• da Cruz e Silva EF, da Cruz e Silva OA. Protein phosphorylation and APP metabolism. Neurochem. Res. 28(10), 1553–1561 (2003).
   PubMed Web of Science ®Google Scholar
• Lee JH, Lau KF, Perkinton MS et al. The neuronal adaptor protein X11α reduces Aβ levels in the brains of Alzheimer’s APPswe Tg2576 transgenic mice. J. Biol. Chem. 278(47), 47025–47029 (2003).
   PubMedGoogle Scholar
• Henriques AG, Vieira SI, da Cruz e Silva EF, da Cruz e Silva OA. Aβ hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. J. Mol. Neurosci. 39(1–2), 248–255 (2009).
   PubMedGoogle Scholar
• Townsend M, Mehta T, Selkoe DJ. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282(46), 33305–33312 (2007).
   PubMed Web of Science ®Google Scholar
• Magdesian MH, Carvalho MM, Mendes FA et al. Amyloid-β binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/β-catenin signaling. J. Biol. Chem. 283(14), 9359–9368 (2008).
   PubMed Web of Science ®Google Scholar
• Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, Sastre M. Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein. Mol. Cell. Biol. 32(21), 4410–4418 (2012).
   PubMed Web of Science ®Google Scholar
• Ly PT, Wu Y, Zou H et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 123(1), 224–235 (2013).
   PubMed Web of Science ®Google Scholar
• Sofola O, Kerr F, Rogers I et al. Inhibition of GSK-3 ameliorates Aβ pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet. 6(9), pii: e1001087 (2010).
   PubMedGoogle Scholar
• Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J. Biol. Chem. 288(2), 1295–1306 (2013).
   PubMed Web of Science ®Google Scholar
• Hooper C, Markevich V, Plattner F et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25(1), 81–86 (2007).
   PubMed Web of Science ®Google Scholar
• Peineau S, Taghibiglou C, Bradley C et al. LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53(5), 703–717 (2007).
   PubMed Web of Science ®Google Scholar
• Peineau S, Nicolas CS, Bortolotto ZA et al. A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol. Brain 2, 22 (2009).
   PubMedGoogle Scholar
• Chen P, Gu Z, Liu W, Yan Z. Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol. Pharmacol. 72(1), 40–51 (2007).
   PubMed Web of Science ®Google Scholar
• Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20(1–2), 27–39 (2001).
   PubMed Web of Science ®Google Scholar
• Peineau S, Bradley C, Taghibiglou C et al. The role of GSK-3 in synaptic plasticity. Br. J. Pharmacol. 153(Suppl. 1), S428–S437 (2008).
   PubMed Web of Science ®Google Scholar
• Wei J, Liu W, Yan Z. Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3. J. Biol. Chem. 285(34), 26369–26376 (2010).
   PubMedGoogle Scholar
• Bradley CA, Peineau S, Taghibiglou C et al. A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 5, 13 (2012).
   PubMedGoogle Scholar
• Tyagarajan SK, Ghosh H, Yévenes GE et al. Regulation of GABAergic synapse formation and plasticity by GSK3β-dependent phosphorylation of gephyrin. Proc. Natl Acad. Sci. USA 108(1), 379–384 (2011).
   PubMed Web of Science ®Google Scholar
• Goñi-Oliver P, Lucas JJ, Avila J, Hernández F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J. Biol. Chem. 282(31), 22406–22413 (2007).
   PubMed Web of Science ®Google Scholar
• Goñi-Oliver P, Avila J, Hernández F. Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer’s disease. J. Alzheimers Dis. 18(4), 843–848 (2009).
   PubMed Web of Science ®Google Scholar
• Goñi-Oliver P, Avila J, Hernández F. Calpain regulates N-terminal interaction of GSK-3β with 14-3-3?, p53 and PKB but not with axin. Neurochem. Int. 59(2), 97–100 (2011).
   PubMedGoogle Scholar
• Shie FS, LeBoeuf RC, Jin LW, LeBoeur RC. Early intraneuronal Aβ deposition in the hippocampus of APP transgenic mice. Neuroreport 14(1), 123–129 (2003).
   PubMedGoogle Scholar
• Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880), 535–539 (2002).
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer’s disease. N. Engl. J. Med. 362(4), 329–344 (2010).
   PubMed Web of Science ®Google Scholar
• Jo J, Whitcomb DJ, Olsen KM et al. Aβ(1–42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 14(5), 545–547 (2011).
   PubMedGoogle Scholar
• Ma T, Hoeffer CA, Capetillo-Zarate E et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer’s disease. PLoS ONE 5(9), pii: e12845 (2010).
   Google Scholar
• Inoki K, Ouyang H, Zhu T et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5), 955–968 (2006).
   PubMed Web of Science ®Google Scholar
• Ittner LM, Ke YD, Delerue F et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell 142(3), 387–397 (2010).
   PubMed Web of Science ®Google Scholar
• Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 287(38), 32040–32053 (2012).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 44(1), 181–193 (2004).
   PubMed Web of Science ®Google Scholar
• Ho VM, Lee JA, Martin KC. The cell biology of synaptic plasticity. Science 334(6056), 623–628 (2011).
   PubMedGoogle Scholar
• Collingridge GL, Peineau S, Howland JG, Wang YT. Long-term depression in the CNS. Nat. Rev. Neurosci. 11(7), 459–473 (2010).
   PubMedGoogle Scholar
• Takashima A. GSK-3β and memory formation. Front. Mol. Neurosci. 5, 47 (2012).
   PubMedGoogle Scholar
• Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Devel. 11(4), 533–543 (2008).
   PubMedGoogle Scholar
• del Ser T, Steinwachs KC, Gertz HJ et al. Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study. J. Alzheimers Dis. 33(1), 205–215 (2013).
   PubMed Web of Science ®Google Scholar